Recombinant human DNase in management of lobar atelectasis due to retained secretions This report suggests that directly instilled rhDNase may be one altemative to conventional therapy for lobar atelectasis. Its use may be beneficial for the subset of patients with lobar atelectasis due to retained secretions which fail to clear with vigorous coughing, chest physiotherapy, and suctioning. Direct bronchoscopic instillation offers the advantage of concentrating it at the site of obstruction and avoids the delay of waiting for the effects of nebulised administration. Further study is warranted comparing rhDNase by direct instillation and nebulisation with traditional respiratory therapy for lobar collapse due to retained secretions. 
Discussion This case reports the first successful use of nebulised liposomal amphotericin B in the treatment ofAspergillus empyema complicating a bronchopleural fistula. Aspergillus empyema is an uncommon condition and is associated with previous tuberculous infection, thoracic surgery, or cytotoxic therapy.' The most likely source of the empyema presented here is rupture of a cavitating pulmonary infarct colonised by Aspergillus fumigatus. The patient was a known asthmatic and the presence of a peripheral eosinophilia, high serum IgE, and positive skin prick tests to Aspergillus supported the diagnosis of bronchopulmonary aspergillosis in addition to the aspergilloma.
Use ofconventional therapy with intravenous and intrapleural amphotericin B failed to control the Aspergillus infection and, moreover, led to a doubling of the creatinine level. Liposomal amphotericin B has been shown to be effective when given intravenously to immunocompromised patients who have failed to respond to conventional amphotericin B."6 It has also been shown to cause less nephrotoxicity.' We chose to administer amphotericin B via the nebulised route because we wished to deliver a high concentration to the lung and felt that the large bronchopleural fistula may lead to direct entry to the pleural space. Indeed, amphotericin activity was detected in the pleural fluid by an imidazole resistant Candida glabata bioassay after 3-8 days oftreatment, after which time there was insufficient pleural fluid for the assay to be performed.
Our patient could not tolerate nebulised amphotericin B because it induced bronchospasm. He was, however, able to tolerate nebulised liposomal amphotericin B and this is the first recorded use of this product in nebulised form in humans. A liposomal vehicle has, however, been well recognised as an attractive means of delivering drugs to the lungs. 7 The role of nebulised liposomal amphotericin B in the successful management of this patient cannot be fully evaluated because of the concomitant administration of itraconazole which has been shown to be effective in a variety ofAspergillus infections,8 and we do not suggest that this report proves an efficacy for liposomal amphotericin B as monotherapy, or even as part of combination therapy, in Aspergillus empyema. We can report that nebulised liposomal amphotericin B was well tolerated by this asthmatic patient and did not lead to any unwanted side effects throughout the six week course of treatment. In particular, renal function was seen to improve to normal levels and there was no hypokalaemia or rise in alkaline phosphatase levels. There was no detrimental effect on pulmonary function. Unfortunately, at approximately £10 000 for the six week course, liposomal amphotericin B was an expensive alternative to conventional amphotericin therapy which would have cost £300 for six weeks at a dosage of 1 mg/kg/day.
Formal studies of nebulised liposomal amphotericin B should be considered to define its role in the management of Aspergillus pulmonary conditions. 
